• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

XRCC1 rs25487 多态性预测乳腺癌术后放化疗患者的生存。

XRCC1 rs25487 polymorphism predicts the survival of patients after postoperative radiotherapy and adjuvant chemotherapy for breast cancer.

机构信息

Cancer Center, Kuopio University Hospital, Kuopio, Finland Institute of Clinical Medicine, Pathology, University of Eastern Finland, Kuopio, Finland Biocenter Kuopio, University of Eastern Finland, Kuopio, Finland Cancer Center of Eastern Finland, University of Eastern Finland, Kuopio, Finland

Institute of Clinical Medicine, Pathology, University of Eastern Finland, Kuopio, Finland Biocenter Kuopio, University of Eastern Finland, Kuopio, Finland Cancer Center of Eastern Finland, University of Eastern Finland, Kuopio, Finland Imaging Center, Pathology, Kuopio University Hospital, Kuopio, Finland.

出版信息

Anticancer Res. 2014 Jun;34(6):3031-7.

PMID:24922669
Abstract

BACKGROUND

Single nucleotide polymorphisms (SNPs) in a DNA-repair gene, X-Ray repair cross complementing group 1 (XRCC1), have been associated with the survival of patients with breast cancer. We investigated the predictive value of XRCC1 SNP (rs25487) in patients with early breast cancer.

PATIENTS AND METHODS

The XRCC1 rs25487 genotypes of 411 Finnish patients with breast cancer were analyzed by a polymerase chain reaction-restriction fragment length polymorphism-based method. Survival was assessed by Kaplan-Meier method and Cox regression analysis according to the XRCC1 genotypes in specified adjuvant treatment groups.

RESULTS

The rs25487 variant AA genotype was associated with worse breast cancer-specific and overall survival in 238 patients receiving postoperative radiotherapy (p=0.031 and p=0.030, respectively). The AA genotype predicted worse breast cancer-specific survival among 75 patients treated with adjuvant chemotherapy (p=0.047).

CONCLUSION

The XRCC1 rs25487 genotype may predict the outcome of postoperative radiotherapy and adjuvant chemotherapy in breast cancer.

摘要

背景

DNA 修复基因 X 射线修复交叉互补组 1(XRCC1)中的单核苷酸多态性(SNPs)与乳腺癌患者的生存有关。我们研究了 XRCC1 SNP(rs25487)在早期乳腺癌患者中的预测价值。

患者和方法

通过聚合酶链反应-限制性片段长度多态性方法分析了 411 例芬兰乳腺癌患者的 XRCC1 rs25487 基因型。根据特定辅助治疗组中的 XRCC1 基因型,通过 Kaplan-Meier 方法和 Cox 回归分析评估生存情况。

结果

在接受术后放疗的 238 例患者中,rs25487 变异 AA 基因型与乳腺癌特异性和总体生存率较差相关(p=0.031 和 p=0.030)。在接受辅助化疗的 75 例患者中,AA 基因型预测乳腺癌特异性生存率较差(p=0.047)。

结论

XRCC1 rs25487 基因型可能预测乳腺癌术后放疗和辅助化疗的结果。

相似文献

1
XRCC1 rs25487 polymorphism predicts the survival of patients after postoperative radiotherapy and adjuvant chemotherapy for breast cancer.XRCC1 rs25487 多态性预测乳腺癌术后放化疗患者的生存。
Anticancer Res. 2014 Jun;34(6):3031-7.
2
Association of the Arg194Trp and the Arg399Gln polymorphisms of the XRCC1 gene with risk occurrence and the response to adjuvant therapy among Polish women with breast cancer.波兰乳腺癌女性中 XRCC1 基因 Arg194Trp 和 Arg399Gln 多态性与风险发生和辅助治疗反应的关联。
Clin Breast Cancer. 2013 Feb;13(1):61-8. doi: 10.1016/j.clbc.2012.09.019. Epub 2012 Oct 26.
3
XRCC1 gene polymorphism for prediction of response and prognosis in the multimodality therapy of patients with locally advanced rectal cancer.XRCC1 基因多态性预测局部晚期直肠癌患者多模态治疗的反应和预后。
J Surg Res. 2010 Nov;164(1):e61-6. doi: 10.1016/j.jss.2010.08.002. Epub 2010 Sep 16.
4
Locoregional recurrence of breast cancer: a retrospective comparison of treatment methods.乳腺癌的局部区域复发:治疗方法的回顾性比较
Neoplasma. 2002;49(6):426-31.
5
Does immediate breast reconstruction after mastectomy and neoadjuvant chemotherapy influence the outcome of patients with non-endocrine responsive breast cancer?乳房切除术后即刻乳房重建及新辅助化疗对非内分泌反应性乳腺癌患者的预后有何影响?
Anticancer Res. 2014 Nov;34(11):6677-83.
6
Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.抗HER2阻断治疗的持续时间可能会改善HER2阳性转移性乳腺癌患者的生存率。
J BUON. 2013 Jul-Sep;18(3):585-93.
7
Human epidermal growth factor receptor-2 positivity predicts locoregional recurrence in patients with T1-T2 breast cancer.人类表皮生长因子受体-2 阳性预测 T1-T2 期乳腺癌患者的局部区域复发。
Anticancer Res. 2014 Mar;34(3):1207-12.
8
Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial.接受新辅助治疗的HER2阳性乳腺癌患者血清中miR-21、miR-210和miR-373水平的变化:Geparquinto试验中的一项转化研究项目
Breast Cancer Res Treat. 2014 Aug;147(1):61-8. doi: 10.1007/s10549-014-3079-3. Epub 2014 Aug 3.
9
Local recurrence patterns in breast cancer patients treated with oncoplastic reduction mammaplasty and radiotherapy.接受肿瘤整形性乳房缩小术和放射治疗的乳腺癌患者的局部复发模式。
Ann Surg Oncol. 2014 Jan;21(1):93-9. doi: 10.1245/s10434-013-3235-8. Epub 2013 Oct 1.
10
Association between a glutathione S-transferase A1 promoter polymorphism and survival after breast cancer treatment.谷胱甘肽S-转移酶A1启动子多态性与乳腺癌治疗后生存率之间的关联。
Int J Cancer. 2003 Mar 1;103(6):810-4. doi: 10.1002/ijc.10896.

引用本文的文献

1
XRCC1: a potential prognostic and immunological biomarker in LGG based on systematic pan-cancer analysis.XRCC1:基于系统泛癌分析的 LGG 潜在预后和免疫生物标志物。
Aging (Albany NY). 2024 Jan 12;16(1):872-910. doi: 10.18632/aging.205426.
2
Identifying Circulating Tumor DNA Mutations Associated with Neoadjuvant Chemotherapy Efficacy in Local Advanced Breast Cancer.鉴定与局部晚期乳腺癌新辅助化疗疗效相关的循环肿瘤 DNA 突变。
Appl Biochem Biotechnol. 2022 Sep;194(9):3961-3973. doi: 10.1007/s12010-022-03946-0.
3
rs1799782 (C194T) polymorphism correlated with tumor metastasis and molecular subtypes in breast cancer.
rs1799782(C194T)多态性与乳腺癌的肿瘤转移和分子亚型相关。
Onco Targets Ther. 2018 Nov 28;11:8435-8444. doi: 10.2147/OTT.S154746. eCollection 2018.
4
Pharmacogenetics of toxicity of 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients.乳腺癌患者中5-氟尿嘧啶、多柔比星和环磷酰胺化疗毒性的药物遗传学
Oncotarget. 2018 Jan 10;9(10):9114-9136. doi: 10.18632/oncotarget.24148. eCollection 2018 Feb 6.
5
Association of XRCC1 Trp194 allele with risk of breast cancer, and Ki67 protein status in breast tumor tissues.XRCC1基因第194位密码子色氨酸等位基因与乳腺癌风险及乳腺肿瘤组织中Ki67蛋白状态的关联。
Saudi Med J. 2016 Jun;37(6):624-30. doi: 10.15537/Smj.2016.6.13540.
6
A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients.碱基切除修复基因PARP2中的一种多态性与绝经后乳腺癌患者化疗后的不同预后相关。
BMC Cancer. 2015 Dec 16;15:978. doi: 10.1186/s12885-015-1957-7.
7
X-ray repair cross-complementing protein 1 and 3 polymorphisms and susceptibility of breast cancer in a Jordanian population.约旦人群中X射线修复交叉互补蛋白1和3基因多态性与乳腺癌易感性
Saudi Med J. 2015 Oct;36(10):1163-7. doi: 10.15537/smj.2015.10.12659.
8
XRCC1 polymorphisms associated with survival among Chinese bladder cancer patients receiving epirubicin and mitomycin C.接受表柔比星和顺铂治疗的中国膀胱癌患者中与生存相关的XRCC1基因多态性
Tumour Biol. 2015 Jun;36(6):4591-6. doi: 10.1007/s13277-015-3104-0. Epub 2015 Jan 25.